Literature DB >> 17636427

Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.

Karen H Lu1.   

Abstract

The main cancer susceptibility syndromes that involve gynecologic cancers include Breast-Ovarian Cancer Syndrome and Lynch Syndrome/Hereditary Non-polyposis Colorectal Cancer Syndrome. For uterine cancer, approximately 5% of all cases are likely due to a hereditary cause and for ovarian cancer, approximately 10% are due to an inherited cause. Gynecologic oncologists play an important role in identifying women with ovarian or endometrial cancer who may have these syndromes. Personal and family history of relevant cancers assists with identification. For those women without cancer who are found to have a hereditary cancer syndrome, effective counseling in the prevention and early detection of cancers is crucial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636427     DOI: 10.1007/s10689-007-9144-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  31 in total

1.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Steven A Narod; Marie-Pierre Dubé; Jan Klijn; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; Diane Provencher; Ketil Heimdal; Pal Moller; Mark Robson; Kenneth Offit; Claudine Isaacs; Barbara Weber; Eitan Friedman; Ruth Gershoni-Baruch; Gad Rennert; Barbara Pasini; Theresa Wagner; Mary Daly; Judy E Garber; Susan L Neuhausen; Peter Ainsworth; Hakan Olsson; Gareth Evans; Michael Osborne; Fergus Couch; William D Foulkes; Ellen Warner; Charmaine Kim-Sing; Olufunmilayo Olopade; Nadine Tung; Howard M Saal; Jeffrey Weitzel; Sofia Merajver; Marion Gauthier-Villars; Helena Jernstrom; Ping Sun; Jean-Sebastien Brunet
Journal:  J Natl Cancer Inst       Date:  2002-12-04       Impact factor: 13.506

2.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

Authors:  B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

3.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Authors:  R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod
Journal:  Am J Hum Genet       Date:  2000-03-16       Impact factor: 11.025

4.  Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.

Authors:  Paul A M Meeuwissen; Caroline Seynaeve; Cecile T M Brekelmans; Hanne J Meijers-Heijboer; Jan G M Klijn; Curt W Burger
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

5.  Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium.

Authors:  A L Millar; T Pal; L Madlensky; C Sherman; L Temple; A Mitri; H Cheng; V Marcus; S Gallinger; M Redston; B Bapat; S Narod
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

6.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

Authors:  K H Lu; J E Garber; D W Cramer; W R Welch; J Niloff; D Schrag; R S Berkowitz; M G Muto
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

7.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.

Authors:  Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

8.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

9.  The reduction in risk of ovarian cancer associated with oral-contraceptive use.

Authors: 
Journal:  N Engl J Med       Date:  1987-03-12       Impact factor: 91.245

Review 10.  Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.

Authors:  Douglas A Levine; Peter A Argenta; Cindy J Yee; David S Marshall; Narciso Olvera; Faina Bogomolniy; Jamal A Rahaman; Mark E Robson; Kenneth Offit; Richard R Barakat; Robert A Soslow; Jeff Boyd
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

View more
  18 in total

1.  A family history questionnaire improves detection of women at risk for hereditary gynecologic cancer: a pilot study.

Authors:  Margot M Koeneman; Arnold-Jan Kruse; Simone J S Sep; Cynthia S Gubbels; Brigitte F M Slangen; Toon van Gorp; Alberto Lopes; Encarna Gomez-Garcia; Roy F P M Kruitwagen
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

2.  Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Authors:  Summer B Dewdney; Nora T Kizer; Abegail A Andaya; Sheri A Babb; Jingqin Luo; David G Mutch; Amy P Schmidt; Louise A Brinton; Russell R Broaddus; Nilsa C Ramirez; Phyllis C Huettner; Donald Scott McMeekin; Kathleen Darcy; Shamshad Ali; Patricia L Judson; Robert S Mannel; Shashikant B Lele; David M O'Malley; Paul J Goodfellow
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-13

Review 3.  Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management.

Authors:  Henry T Lynch; Jane F Lynch; Patrick M Lynch; Thomas Attard
Journal:  Fam Cancer       Date:  2007-11-13       Impact factor: 2.375

4.  Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.

Authors:  Hidetaka Nomura; Masayuki Sekine; Shiro Yokoyama; Masami Arai; Takayuki Enomoto; Nobuhiro Takeshima; Seigo Nakamura
Journal:  Int J Clin Oncol       Date:  2019-05-04       Impact factor: 3.402

Review 5.  Epidemiological and genetic factors associated with ovarian cancer.

Authors:  Monica R McLemore; Christine Miaskowski; Bradley E Aouizerat; Lee-May Chen; Marylin J Dodd
Journal:  Cancer Nurs       Date:  2009 Jul-Aug       Impact factor: 2.592

6.  BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Authors:  Pierosandro Tagliaferri; Monica Ventura; Francesco Baudi; Iole Cucinotto; Mariamena Arbitrio; Maria Teresa Di Martino; Pierfrancesco Tassone
Journal:  J Ovarian Res       Date:  2009-10-13       Impact factor: 4.234

Review 7.  Genetic polymorphisms and endometrial cancer risk.

Authors:  Larissa A Meyer; Shannon N Westin; Karen H Lu; Michael R Milam
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 8.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

9.  Development of an integrated support system for hereditary cancer and its impact on gynecologic services.

Authors:  Mina Morii-Kashima; Hiroshi Tsubamoto; Chika Sato; Mariko Ushioda; Naohiro Tomita; Yasuo Miyoshi; Tomoko Hashimoto-Tamaoki; Kazuo Tamura; Hideaki Sawai; Hiroaki Shibahara
Journal:  Int J Clin Oncol       Date:  2013-12-19       Impact factor: 3.402

10.  Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.

Authors:  Lotte H M Gerritzen; Nicoline Hoogerbrugge; Angèle L M Oei; Fokko M Nagengast; Maaike A P C van Ham; Leon F A G Massuger; Joanne A de Hullu
Journal:  Fam Cancer       Date:  2009-06-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.